Stock DiscoverySign in
Back to Discover

Altimmune, Inc.

ALT · Biotech · Nasdaq · As of 10 Sep 2026
49AIR SCORE
  • FundamentalsNot enough data yet
  • ValueNot enough data yet
  • News flowBalanced
  • MomentumWatch
  • SafetyBalanced

Overall confidence 38/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Low (0/100) · Gap confidence 39/100The market has largely caught up to the documented story.

This month at a glance

AIR Score™ change: -1Slipped -1 on softer inputs.
Cycle window9 Sep 2026 → 10 Sep 2026
Momentum-1Weighed on the latest score.

Evidence timeline

  1. [8-K 2.02] Altimmune, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Aug 12, 2026 · 8-K
  2. [8-K 8.01] Altimmune, Inc. — Other EventsSEC · SEC EDGAR
    Jul 28, 2026 · 8-K
  3. [8-K 8.01] Altimmune, Inc. — Other EventsSEC · SEC EDGAR
    Jun 16, 2026 · FORM 8-K
  4. [8-K 2.02] Altimmune, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    May 13, 2026 · 8-K
  5. [8-K 1.01] Altimmune, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
    Apr 22, 2026 · FORM 8-K
  6. [8-K 2.02] Altimmune, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Mar 5, 2026 · 8-K
  7. [8-K 8.01] Altimmune, Inc. — Other EventsSEC · SEC EDGAR
    Feb 2, 2026 · 8-K
  8. [8-K 1.01] Altimmune, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
    Jan 27, 2026 · 8-K
  9. [8-K 8.01] Altimmune, Inc. — Other EventsSEC · SEC EDGAR
    Dec 19, 2025 · FORM 8-K
  10. [8-K 5.02] Altimmune, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Nov 30, 2025 · FORM 8-K
  11. [8-K 1.02] Altimmune, Inc. — Termination of a Material Definitive AgreementSEC · SEC EDGAR
    Nov 6, 2025 · 8-K
  12. [8-K 1.01] Altimmune, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
    Nov 6, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.